SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 31, 2007
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
PENNSYLVANIA
(State or Other Jurisdiction of
Incorporation)
|
|
1-14131
(Commission
File Number)
|
|
23-2472830
(I.R.S. Employer
Identification No.) |
| |
|
|
88 Sidney Street
Cambridge, Massachusetts
(Address of principal executive offices)
|
|
02139
(Zip Code) |
Registrant’s telephone number, including area code: (617) 494-0171
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events
On October 31, 2007, Alkermes, Inc. issued a press release announcing positive results from a
30-week comparator study of once-weekly exenatide long-acting release (LAR) injection and
BYETTA® (exenatide) injection taken twice daily in patients with type 2 diabetes.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| |
|
|
| |
|
|
| Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Press release issued by Alkermes,
Inc. dated October 31, 2007
announcing positive results from a 30-week comparator study of
once-weekly exenatide long-acting release (LAR) injection and
BYETTA® (exenatide) injection taken twice daily in
patients with type 2 diabetes. |